PhoenixBio Group would like to express its gratitude to the valued clients and collaborators! Our success is the result of your continuous trust and support!
Your front-edge research resulted in 94 presentations on PXB-Mouse® and PXB-cells® at 19 conferences!
To satisfy your growing demand in PXB-cells® and address the concern of shipment costs, we started PXB-cells® (~95% pure fresh human hepatocytes) production in Edmonton (Canada).
PXB-Mouse® use for NASH drug development was published in 2018 by the client from pharmaceutical industry.
Another customer from the pharmaceutical industry helped us to establish dually infected with hepatitis B and hepatitis Delta PXB-Mouse® (HBV/HDV-infected model).
Academic collaborators helped us to show that PXB-Mouse® can be successfully infected with malaria – P.vivax.
We look forward to another productive year ahead. We would be pleased to support your research in all application areas.